This work was financially supported by the Research Council of Norway, the University of Oslo, the Anders Jahre Foundation, the Nansen Foundation, and the Legacy in the memory of Henrik Homan. We thank Dr. Noboru Mizushima for the ATG5+/+ MEFs and ATG5-/- MEFs, Dr. Masaaki Komatsu for the ATG7+/+ MEFs and ATG7-/- MEFs, and Dr. Shizuo Akira for the ATG9A+/+ MEFs and ATG9A-/- MEFs. We thank Frank S&#230;tre for technical assistance, and Dr. Per O. Seglen for constructive methodological discussions.

1. Cell Seeding and Treatment
<ol>
	<li>Culture adherent cells in 75 cm2 tissue culture flasks in a humidified incubator with 5% CO2 at 37 &#176;C, using the preferred culture medium for the cell type in question. Allow the cells to grow until they reach a near-confluent cell layer. 
	NOTE: Use RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) for LNCaP, HEK293, mouse embryonic fibroblasts (MEFs), BJ, MCF-7, and RPE-1 cells.
	<ol>
		<li>Wash the cells with 3 mL&#160;37 &#176;C phosphate-buffered saline (PBS), pH 7.4. Replace the PBS with 3 mL&#160;0.25% (w/v) Trypsin-ethylenediaminetetraacetate (EDTA), and incubate the flask in a humidified incubator with 5% CO2 at 37 &#176;C until the cells detach (2&#8211;5 min).</li>
		<li>Resuspend the detached cells with 7 mL&#160;culture medium containing 10% FBS. Mix a 10 &#181;L cell suspension aliquot with 10 &#181;L 0.4% Trypan Blue in a microcentrifuge tube, using a 0.5&#8211;20 &#181;L pipette tip. Use the same pipette tip to immediately fill a counting chamber slide, and count the cells in an automated cell counter.</li>
	</ol>
	</li>
	<li>Prepare a suitable dilution (see note below) of the cell suspension from step 1.1.2 using culture medium containing 10% FBS, and seed 1&#160;mL of the diluted cell suspension in each well of a 12-well tissue culture plate (surface area ~3.8 cm2) using aseptic technique. Allow growth in a humidified incubator with 5% CO2 at 37 &#176;C until the desired cell density has been reached, e.g., 60&#8211;90% confluence at harvest. 
	NOTE: The appropriate dilution of the cell suspension that will give the desired cell confluency at harvest will vary from cell type to cell type, as well as according to the duration and type of experimental treatments. Thus, this must be empirically assessed in each case.
	<ol>
		<li>For experiments that are to be both treated and harvested 2 days after seeding, seed 2.5 x 105 LNCaP,&#160;HEK293, or MCF-7 cells, 5 x 104 MEFs, 4 x 105 BJ, or 1.5 x 105 RPE-1&#160;cells in each well of the 12-well plate.</li>
		<li>For cells that adhere loosely, coat the plates with the type of coating recommended for the cell type in question. For LNCaP (and HEK293) cells use plates coated with poly-D-lysine (PDL).</li>
		<li>To that end, add 500 &#181;L PDL at 2.5 &#181;g/mL in sterile H2O to each well, and incubate the plates in a sterile environment for 30 min at room temperature (20&#8211;25 &#176;C). Remove the PDL with suction, and wash each well briefly with 1 mL sterile H2O. 
		NOTE: Generally, step 1.2.1 is done without any experimental treatments. However, if performing RNAi, it may be convenient to start a reverse transfection with the seeding9.</li>
	</ol>
	</li>
	<li>Perform experimental treatments in duplicate or triplicate wells per condition.
	<ol>
		<li>For example, treat the cells with 50 nM of the mTOR-inhibitor Torin1, which generally is an efficient inducer of autophagic sequestration, or subject the cells to acute serum- and amino acid starvation by washing the cells with 1 mL of amino acid-free Earle&#39;s Balanced Salt Solution (EBSS) medium, and subsequently incubate the cells in 1 mL of EBSS in a humidified incubator with 5% CO2 at 37 &#176;C.</li>
		<li>Leave one set of wells untreated in order to define background levels of sedimentable LDH.</li>
		<li>Add a saturating amount of the post-sequestration inhibitor bafilomycin A1 (Baf)3,13,16,18 in the absence or presence of the experimental treatments, 3&#8211;4 h before cell harvest. Incubate the cells in a humidified incubator with 5% CO2 at 37 &#176;C.
		<ol>
			<li>Use 100 nM Baf for LNCaP, HEK293, BJ, MCF-7 and RPE-1 cells, and 10 nM Baf for MEFs.</li>
			<li>For experimental treatments that&#160;have a duration of only 3&#8211;4 h (like those exemplified in step 1.3.1 typically have), add Baf simultaneously with the treatments. For longer experimental treatments, wait until 3-4 h before harvest, and add 2 &#181;L&#160;of a 500x concentrated Baf stock directly into the medium.</li>
			<li>Mix by agitating the plate immediately after the addition of Baf. At this point it is also recommendable to add macroautophagic sequestration inhibitors as controls, e.g., 10 mM of the pan-phosphoinositide 3-kinase (PI3K) inhibitor 3-methyl adenine (3MA)19, or 10 &#181;M of the selective PI3K class III inhibitor SAR-40520.</li>
		</ol>
		</li>
	</ol>
	</li>
</ol>
2. Cell Harvest and Preparation for Electrodisruption
<ol>
	<li>At the end of the treatment period, aspirate the medium with suction and add 200 &#181;L cell detachment solution (pre-heated to 37 &#176;C) to each well. Incubate at 37 &#176;C until the cells detach (typically around 5 min). 
	NOTE: Whereas 0.25% (w/v) Trypsin-EDTA may be used instead of the cell detachment solution, the latter contains DNase, which helps reduce the viscosity of the detached cells. As long as the medium is thoroughly aspirated, it is not necessary to wash the cells before addition of Trypsin-EDTA or cell detachment solution.</li>
	<li>Add 500 &#181;L room temperature (20-25 &#176;C) PBS, pH 7.4, containing 2% (w/v) bovine serum albumin (BSA) to each well, and resuspend with the pipette until no cell clumps are visible. Immediately transfer the cell suspension to 1.5 mL microcentrifuge tubes on ice. 
	NOTE: Unless otherwise stated, perform all subsequent steps on ice.</li>
	<li>Sediment the cells by centrifugation at 400 x g for 5 min at 4 &#176;C.</li>
	<li>Thoroughly aspirate the supernatant (with suction) to leave the cell pellets as dry as possible.</li>
	<li>Add 400 &#181;L 10% (w/v) sucrose (in ultrapure H2O) to each tube.</li>
</ol>
3. Plasma Membrane Electrodisruption and Separation of Sedimentable- and Total-cell Fractions
<ol>
	<li>Resuspend the cell pellet with a pipette to obtain a near single-cell suspension, and transfer it to a 4 mm electroporation cuvette. 
	NOTE: Pipetting up-and-down ~10&#8211;15 times, using a 100&#8211;1,000 &#181;L pipette tip, is usually sufficient.</li>
	<li>Place the cuvette in an exponential decay wave electroporator, and discharge a single electric pulse at 800 V, 25 &#181;F, and 400 &#8486;; these settings produce a pulse of ~8 ms duration.</li>
	<li>Use a new pipette tip to transfer the cell disruptate to a 1.5 mL microcentrifuge tube containing 400 &#181;L ice-cold phosphate-buffered sucrose solution (100 mM sodium monophosphate, 2 mM dithiothreitol (DTT), 2 mM EDTA, and 1.75% sucrose, pH 7.5), and mix briefly by pipetting.
	<ol>
		<li>Optional: To verify efficient plasma membrane electrodisruption17, mix 10 &#181;L of the diluted cell disruptate from step 3.3 with 10 &#181;L 0.4% Trypan Blue in a 1.5 mL microcentrifuge tube. Transfer to a counting chamber and verify that the percentage of Trypan Blue positive cells is &#62;99%.
		<ol>
			<li>Leave the sample in the counting chamber for 30 min at room temperature (20&#8211;25 &#176;C), and verify that the percentage of Trypan Blue positive cells has remained &#62;99%.</li>
		</ol>
		</li>
		<li>Optional: To verify that the electrodisruption has not been too harsh, that is, it has not disrupted intracellular organelles, perform steps 1.1&#8211;3.3 as described above, but use a larger starting material (a well from a 6-well plate with an ~80% confluent cell layer), and use 150 &#181;L 10% sucrose in step 2.5 and 150 &#181;L phosphate-buffered sucrose solution without DTT in step 3.3.
		<ol>
			<li>Use a pipette to carefully layer 200 &#181;L of the diluted cell disruptate solution on top of a 1.2 mL density cushion of phosphate-buffered 8% (w/v) density gradient medium (e.g, 8% Nycodenz, 50 mM sodium phosphate, 2.2% sucrose, 1 mM EDTA) in a 2 mL centrifuge tube. Centrifuge at 20,000 x g for 45 min at 4 &#176;C in a microcentrifuge with soft-mode function (for gentle acceleration and deceleration), and carefully put the tubes on ice.</li>
			<li>Carefully remove 60 &#181;L of the ~200 &#181;L top fraction, making sure not to pick up any density gradient medium solution, and transfer to a fresh microcentrifuge tube. 
			NOTE: This should contain cytosol of exceptional purity, termed &#34;cell sap&#34;21.</li>
			<li>Test the purity of the fraction obtained in the above step, by performing western blot analyses of organelle-contained proteins, using standard techniques and 4&#8211;20% gradient gels16.</li>
			<li>Perform for example immunoblotting for cathepsin B21, cytochrome c, and protein disulphide isomerase, to verify that the electric shock in step 3.2 has not disrupted lysosomes, mitochondria, or endoplasmic reticulum, respectively, and immunoblot for LDH to verify presence of a cytosolic protein in the cell sap.</li>
			<li>In parallel, perform immunoblotting on protein extracts made from the total cell disruptate solution16 to confirm that the antibodies used can detect the organelle-contained proteins that are being assessed.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Repeat steps 3.1&#8211;3.3 for each sample.</li>
	<li>Remove 550 &#181;L from each diluted cell disruptate solution (obtained at step 3.3) to 2 mL microcentrifuge tubes containing 900 &#181;L ice-cold resuspension buffer (50 mM sodium monophosphate, 1 mM DTT, 1 mM EDTA, and 5.9% sucrose, pH 7.5) supplemented with 0.5% BSA and 0.01% Tween-20, and mix briefly by pipetting.</li>
	<li>Centrifuge at 18,000 x g for 45 min at 4 &#176;C to produce pellets containing &#34;sedimented LDH&#34;. Thoroughly aspirate the supernatant (with suction) to leave the pellets as dry as possible. Place the samples in a -80 &#176;C freezer.</li>
	<li>Transfer 150 &#181;L from each diluted cell disruptate solution (obtained at step 3.3) to new tubes, and place the samples in a -80 &#176;C freezer. Use these samples to determine the &#34;total LDH&#34; levels in the cells. 
	NOTE: At this point the experiment can be paused for as long as desired.</li>
</ol>
4. LDH Extraction and Measurement of LDH Enzymatic Activity
<ol>
	<li>Thaw the &#34;sedimented LDH&#34; (from step 3.6) and &#34;total LDH&#34; samples (from step 3.7) on ice.</li>
	<li>Add 300 &#181;L of ice-cold resuspension buffer containing 1.5% Triton X-405 to the &#34;total LDH&#34; samples (yielding a final Triton X-405 concentration of 1%). Rotate the samples on a roller in a cold room (4&#8211;8 &#176;C) for 30 min.</li>
	<li>Add 750 &#181;L of ice-cold resuspension buffer with 1% Triton X-405 to the &#34;sedimented LDH&#34; samples, and resuspend the pellets with a pipette until a homogenous solution is reached.</li>
	<li>Centrifuge the samples from step 4.2 and 4.3 at 18,000 x g for 5 min at 4 &#176;C&#160;to sediment undissolved cellular debris.</li>
	<li>Mix 4 parts of cold 65 mM imidazole (pH 7.5)/0.75 mM pyruvate with one part of cold 65 mM imidazole (pH 7.5)/1.8 mM NADH to obtain a working solution that is stable for at least three weeks at 4 &#176;C.</li>
	<li>Mix 3&#8211;30 &#181;L of the supernatants from step 4.4 with 200 &#181;L of the step 4.5 working solution.</li>
	<li>Determine the amount of LDH by measuring LDH enzymatic activity as the decline in nicotinamide adenine dinucleotide (reduced form) (NADH) absorbance at 340 nm at 37 &#176;C compared to a standard with a known LDH concentration. Perform absorbance measurements&#160;until the reaction has approached completion, i.e. until the absorbance at 340 nm no longer changes with time. 
	NOTE: This is the classical biochemical method to measure LDH activity. Although the current protocol performs the reaction at 37 &#176;C, it can also be performed at room temperature (20&#8211;25 &#176;C), which is advisable if doing manual spectrophotometry. The current protocol uses a robotic multianalyzer instrument, which in an automated fashion mixes samples with working solution in a 96-well plate, and measures the absorbance at 340 nm at 37 &#176;C every 20 s for 3 min. Thereafter, the instrument software calculates the concentration of LDH, expressed as Units (U)/L, by comparing the slope of the absorbance measurements over time compared to a standard curve obtained through&#160;calibration with a standard of known LDH concentration. The linear range of detection by this approach is 30&#8211;1,500 U/L. As an alternative, a wide variety of commercially available kits to measure LDH exist. Some of them are based on coupling the enzymatic reaction to the generation of colorimetric or fluorescent products, enabling detection by other means than UV spectrophotometry, and with other linear ranges of detection.</li>
</ol>
5. Calculation of LDH Sequestration
<ol>
	<li>Calculate the percentage of sedimented LDH to total LDH for each sample, taking the dilutions and sampling into account: 
	Sedimented LDH (%) = <img alt="Equation 1" src="/files/ftp_upload/57971/57971eq1.jpg" /> 
	NOTE: During steps 3.1&#8211;3.3 approximately 50 &#181;L is lost due to transfer into and out of the electroporation cuvette. Thus, calculate from having a total of 750 &#181;L (instead of 800 &#181;L) of diluted cell disruptate in step 3.3.</li>
	<li>Subtract the percentage of sedimented LDH obtained in the samples from untreated cells (step 1.3.2) from the percentage of sedimented LDH obtained in samples from experimentally treated cells, and divide by the treatment time with Baf to obtain the percentage of sequestered LDH per hour in the sampling period: 
	Sequestered LDH (%/h) = <img alt="Equation 2" src="/files/ftp_upload/57971/57971eq2.jpg" /></li>
</ol>

The authors have no conflict of interest.

In summary, the protocol described here represents a reliable and widely applicable method to monitor bulk autophagic sequestration activity in mammalian cells. Compared to the original method12,16, we have removed a number of unnecessary steps, simplified several of the remaining steps, and introduced a substantial downscaling. As a result, the protocol is greatly improved in relation to cost- and time-efficiency, and the same amount of samples can now be handled in less than half the time as compared to the original protocol. For 24 samples, steps 2&#8211;3 (day 1) requires approximately &#189; h of preparation plus 3 h of efficient work, whereas step 4 (day 2) can be performed in ~2 h (time estimates given that all the necessary buffers are prepared beforehand). Since the assay on day 1 usually is preceded by cell treatments, including a 3&#8211;4 h incubation with Baf or other inhibitors of autolysosomal LDH degradation, it is convenient to divide the assay in two consecutive days. However, it is also possible to perform the whole assay in one and the same day. In that case, it would save time to snap-freeze the samples in liquid nitrogen in step 3.6&#160;and 3.7. Although not tested&#160;with the current protocol, it is likely that the freeze-thaw step may be skipped altogether, since the more elaborate version of the assay in primary rat hepatocytes has been done without this step23.
The protocol presented here can be performed with relative ease. Of note, it is important to be accurate in the pipetting, since the assay includes several sampling and dilution steps. Moreover, the supernatant aspirations should be done thoroughly, so that minimal amounts of ions are present in the sucrose cell suspension in step 2.5, and so that as little cytosolic LDH as possible is contaminating the sedimented material in step 3.6. The assay as described here is flexible for a wide range of starting material. For example, in LNCaP cells, we have successfully used the assay with a range of different amounts of cells at harvest, spanning up to a 10-fold difference (from 2.5 x 105 cells to 2.5 x 106 cells). The minimum starting material needed is defined by how sensitive the detection method of LDH enzymatic activity is. The protocol can very likely be scaled substantially further down, by scaling down the volumes used at steps 2.5, 3.3, 3.5, 3.7, 4.2, and 4.3.
The most critical factor and technical challenge with the assay is the electrodisruption step. The strong, but brief, electric shock of cells in ion-free, isotonic solution results in a uniform and selective disruption of the plasma membrane, while leaving intracellular structure and organelles (including autophagic vacuoles) intact12,29. When using adherent cells, it is essential that they tolerate the enzymatic and mechanical treatments in steps 2.1&#8211;3.1 (cell detachment, centrifugation, and resuspension). For step 3.1, it is not critical to obtain a perfectly single-cell suspension. For example, this is very hard to achieve with LNCaP cells. Nevertheless, successful electrodisruption in near 100% of the cells is always obtained, even within cell clumps containing several dozens of physically attached cells. When testing a new cell type, it is advisable to verify the efficiency of the electrodisruption (see step 3.3.1)17. Close to 100% of the cells should be permanently Trypan Blue positive after the electrodisruption step17. If this is not the case, the electroporator settings must most likely be altered. Using the assay in 20 different mammalian cell types, we have never had to change the electroporator settings. Thus, once the right settings have been found for one mammalian cell line, it is likely to work for all other types of mammalian cells. To verify that the electrodisruption conditions are not too harsh, i.e.,that only the plasma membrane, and not the membranes of intracellular organelles have been disrupted, follow step 3.3.2.
Bulk autophagy is performed by autophagosomes that co-sequester substantial amounts of cytosol along with other cargo. This may happen via purely non-selective autophagy of portions of the cytoplasm, or in a manner that represents a mix of selective and non-selective autophagy. To date it is not clear whether or to which degree selective and non-selective autophagy co-exist as two different modes of autophagy, or whether autophagosomes as a rule simultaneously sequester cargo in both selective and non-selective manners. Importantly, however, a&#160;recent study reported that activators of selective autophagy induce a similar increase in bulk cytosolic cargo sequestration as in the sequestration of the specific cargo30. Results from our own laboratory are in agreement with this (our unpublished results). Analyzing the sequestration of soluble cytosolic proteins (e.g., LDH) therefore likely has the potential to detect alterations in macroautophagic sequestration activity under many, if not all conditions. However, although it still remains to be proven, the possibility cannot be excluded that certain types of conditions uniquely induce a type of selective-exclusive autophagy where the cargo is so tightly wrapped by the phagophore that even cytosol is excluded from being sequestered into the autophagosome. To probe for whether such condition may exist, bulk autophagy assays like the LDH sequestration assay should be run in parallel with selective autophagy assays.
One of the main advantages of the LDH sequestration assay is that it measures the sequestration of endogenous cargo,&#160;thus making it a broadly applicable method. Moreover, the assay measures sequestration activity in a highly quantitative manner. The LDH sequestration assay is an important tool for studying the mechanisms and regulation of autophagosome formation, since open phagophores cannot sequester LDH. It is very cumbersome and difficult, if not impossible, to assess whether autophagosome-like structures are sealed entities or not by electron microscopy. Another method that is being used to analyze whether autophagosomes are closed is to test the sensitivity of autophagy markers (e.g., LC3) or receptors (e.g., sequestosome 1 (p62/SQSTM1) or nuclear dot protein 52 (NDP52)) to proteases10,31,32. The disadvantage of this assay is that one is studying protease protection of cart components rather than autophagic cargo. Moreover, since the assay is based on western blotting, it is only semi-quantitative.
Whereas the ability to analyze autophagy of endogenous cargo is an advantage, an inherent limitation with the LDH sequestration assay, and any other assays that assess sequestration of endogenous cargo, is that a degradation inhibitor must be included in order to discern specific effects on autophagic sequestration rather than net effects of sequestration and degradation. Efficient inhibitors of LDH degradation include proton pump inhibitors like Baf or concanamycin A3,16,18, and lysosomotropic agents like chloroquine and ammonium chloride33. The protease inhibitor leupeptin works well in primary rat hepatocytes23, but is generally inefficient in the mammalian cell lines we have tested. We routinely use Baf13, which acts rapidly and is highly efficient in both nonmalignant and malignant cells. However, it is important to keep in mind that none of the LDH degradation inhibitors are entirely specific, and putative effects of the inhibitors on autophagy cannot be excluded. To minimize the risk of non-specific influence, it is recommendable to use concentrations of the inhibitor that are just at saturating levels, and to include the inhibitor only for the last few hours (3&#8211;4 h) of the experiment. The saturating concentration of Baf should be determined for each cell type. As a guide, 50&#8211;100 nM is saturating for most of the cultured mammalian cell lines we have tested, whereas some cell types such as MEFs require only 10 nM Baf for a full block in LDH degradation.
An obvious limitation with the LDH sequestration assay is that it can only be performed on living cells, thus excluding its use for analysis of autophagy in fixed cells and tissues. On the other hand, there are currently no assays established that can measure functional autophagic activity in fixed cells. Although not tested with the current protocol, it should be entirely possible to use the LDH sequestration assay to assess in vivo autophagic sequestration activity in experimental organisms. The limitation would be that the organism must tolerate treatment with an inhibitor of lysosomal LDH degradation, and that the time period between such treatment and performance of the assay should be relatively short, to minimize potential non-specific effects of the inhibitor. Interestingly, an early study by Kominami et al., indicated that 3&#8211;6 h treatment of rats with leupeptin (intraperitoneal injection of 2 mg/100 g of body weight) is appropriate to observe efficient accumulation of autophagically sequestered LDH in liver subcellular fractions enriched for autophagic vacuoles34.
Ectopic expression of pH-sensitive fluorescent sequestration probes such as Rosella35 or Keima36 can be used to visualize autophagic sequestration without the need of including degradation inhibitors. Moreover, unlike the LDH sequestration assay, such approaches can be used to visualize autophagic sequestration in single cells. Additionally, fusion of the probe to organelle-targeting sequences can be utilized to monitor sequestration of specific organelles. Powerful microscopic platforms may also allow for high-throughput screening analyses. The disadvantages are that ectopic probe expression, as well as accumulation of the probe in the lysosomal system, may influence the autophagic pathway. Moreover, unlike the LDH sequestration assay, one is dependent on cells that can be efficiently transfected. Finally, whereas the LDH sequestration assay provides a straight-forward quantitative output of percentage sequestered cytosol, the image-based methods generally cannot provide this type of absolute quantitative output. It would be advisable to make use of both types of approaches in a complementary manner. Another excellent method to study autophagic sequestration without a need for degradation inhibitors is to introduce radiolabeled raffinose into cells by reversible electro-permeabilization3,23,37,38. Raffinose is a membrane-impermeant and metabolically inert sugar that is resistant to lysosomal enzymes. Therefore, its autophagic sequestration can be followed by separation of cytosolic from sedimentable cell fractions3,23,37,38. This approach is, however, more time-consuming than the LDH sequestration assay, and requires additional safety precautions due to the use of radioactivity. Finally, the end-result of bulk autophagic sequestration and unobstructed autophagic cargo flux, the degradation of long-lived proteins, can be accurately measured by a well-established protein labelling-based method39,40,41,42,43. However, unlike the LDH sequestration assay, this method does not provide a specific read-out for autophagic activity, since long-lived proteins are degraded also by other mechanisms than autophagy, most notably by the proteasomal system (whereas LDH sequestration only occurs as a result of autophagy). Therefore, a number of control treatments need to be routinely included, e.g., chemical inhibitors of autophagic-lysosomal or proteasomal degradation, and genetic interference with autophagy3,16.
The LDH sequestration assay can be compared with the commonly used LC3 flux assays, which measure LC3-II levels by western blotting or LC3 puncta formation by fluorescence imaging in the absence or presence of inhibitors of lysosomal LC3 degradation (Baf is most frequently used), or the transition of fluorescently tagged LC3 variants to acidic environments22. Although these LC3-based assays may provide useful information, they can be difficult to interpret, in particular because the relationship between the degree of LC3 flux and the amount and type of cargo flux is unknown. As mentioned in the introduction, bulk autophagy and Parkin-dependent mitophagy do not require LC3 family proteins9,10,11,44. Moreover, in starved rat hepatocytes, LDH sequestration and degradation proceeds uninterrupted during time periods where there is no autophagic-lysosomal LC3 flux9. Thus, in this case, cargo flux can be completely separated from LC3 flux. More research comparing LC3 flux with different kinds of cargo flux is needed to better interpret results obtained with LC3 flux assays.
In its present form, the LDH sequestration assay is comparable to western blotting in terms of the required hands-on time and costs. In terms of measuring bulk autophagy, it is at least as efficient as the raffinose-based sequestration assay or the long-lived protein degradation assay described above. For specific measurement of bulk autophagic sequestration activity and formation of closed autophagosomes, it is much more efficient and straight-forward than LC3 flux assays or protease protection assays of LC3 or autophagy receptors, since the latter assays measure cart components rather than actual cargo. Even though we have substantially improved the throughput of the LDH sequestration assay, it is far from a high-throughput assay, and it cannot compete with the efficiency of the image-based assays described above. However, both the image-based assays and the LDH sequestration assay have their advantages and disadvantages, and thus both types of assays have their own values. It is likely possible via future adjustments to make the LDH sequestration assay semi high-throughput. For example, it should be possible to perform electrodisruption in a 96-well format, and it is conceivable that cytosolic LDH could be separated from sequestered LDH by filtration instead of centrifugation, or that the centrifugation step can be performed in a 96-well format. Moreover, assays to measure LDH activity that are much more sensitive than that used in the current protocol have been developed, and are commercially available. Other interesting future potentials of the assay are its putative use in other cell types than mammalian cells, for instance in yeast or other unicellular organisms, or even plant cells, as well as its use for in vivo measurements of autophagic sequestration activities in tissues of experimental organisms.
In conclusion, we believe that the LDH sequestration assay in its improved and revived form will be an important tool in future autophagy-related research.

Autophagy (Greek for &#34;self-eating&#34;) is an evolutionary conserved process for vacuolar/lysosomal degradation of intracellular material. Upon discovery of the autophagy-related (&#34;ATG&#34;) genes, which are important for autophagy in yeast and humans, and the realization that autophagy plays a significant role in human health and disease (acknowledged by the 2016 Nobel Prize in Medicine or Physiology to Yoshinori Ohsumi), autophagy has quickly become one of the most intensely studied processes in cell biology1,2.
Macroautophagy (hereafter referred to as &#34;autophagy&#34;) is characterized by the expansion and folding of intracellular membrane cisternae (&#34;phagophores&#34;) into sealed, double- or multi-membrane structures (&#34;autophagosomes&#34;) that effectively sequester the enwrapped material from the rest of the cytoplasm. Upon fusion of autophagosomes with lysosomes, the inner autophagosomal membrane and the sequestered cargo is degraded and recycled. Autophagosomes can sequester cytoplasmic material in both random (non-selective autophagy) and selective (selective autophagy) manners. Bulk autophagy most likely represents a mix of non-selective and selective autophagy.
In the 1960&#39;s and 70&#39;s (&#34;the morphological era&#34; of autophagy research), autophagic sequestration was mainly assessed through ultrastructural analyses. In the 1980&#39;s and beginning of the 1990&#39;s (&#34;the biochemical era&#34;) Per Seglen and co-workers &#8212; who studied autophagy in primary rat hepatocytes &#8212; developed the first methods to quantitatively measure autophagic sequestration activity3. Using these assays, Seglen defined and characterized different steps of the autophagic-lysosomal pathway4,5, discovered and coined the amphisome6 (the product of endosome-autophagosome fusion), and was the first to describe the role of protein phosphorylation in autophagy regulation7. However, after the discovery of the ATGs in the 1990&#39;s (&#34;the molecular&#160;era&#34;) and the first characterization of a mammalian ATG8 protein, microtubule-associated protein 1A/1B-light chain 3 (LC3) in 20008, the use of ATG proteins as markers for the autophagic process quickly gained popularity, and the older and more laborious biochemical methods were left behind. In fact, over the last 18 years, western blot and fluorescence microscopy analyses of LC3 have become the by far most popular (and in many cases the only) means of studying autophagy in mammalian cells. The advantage is the relative ease by which these methods can be carried out. The disadvantage is that one is studying a cart component (LC3) rather than actual autophagic cargo. This is a rather serious disadvantage, because the relationship between the states and/or flux of LC3 through the pathway versus the sequestration and flux of cargo is highly unclear. In fact, we have shown that bulk cargo flux can be maintained at high levels under conditions where there is no LC3 flux, despite the presence of conjugated LC3 in the cells9. Moreover, we demonstrated that bulk autophagy is unaffected by efficient LC3 depletion, and thus likely is LC3-independent9. This finding has later been confirmed by LC3 knock-out studies10,11, which also indicate that Parkin-dependent mitophagy (the selective autophagy of mitochondria) is independent of LC310,11.
In summary, there is a clear need for cargo-based assays to monitor autophagic activity. Optimally such assays should be broadly applicable, well-defined, and easy to perform. Over the last few years we have taken a particular interest in the LDH sequestration assay, which was developed by Per Seglen in the 1980&#39;s12, and is based on measuring the transfer of cytosolic LDH to sedimentable, autophagic vacuole-containing cell fractions. LDH is a stable, soluble cytosolic protein that is readily co-sequestered when phagophores enwrap cytoplasmic cargo. Sequestration of LDH is therefore a general measure of autophagic sequestration. LDH is exclusively degraded by the autophagic-lysosomal pathway12. Thus, in the presence of lysosomal degradation inhibitors, e.g., bafilomycin A1 (Baf)13, experimental treatment effects directly reflect alterations in autophagic sequestration activity. In the absence of degradation inhibitors, the net effect of alterations in LDH sequestration and degradation can be measured.
The LDH sequestration assay is broadly applicable, since LDH is highly and ubiquitously expressed in all cell types, and LDH levels can be accurately quantified by an enzymatic assay14,15. However, the original protocol12 &#8212; established in primary rat hepatocytes &#8212; was rather time-consuming and required a high amount of starting material as well as a custom-made electric discharge capacitor. In a step-wise manner, we have gradually transformed the assay into an easy and versatile method. First, the original protocol was adapted for use in mammalian cell lines16. Second, the method was substantially downscaled3,9. Third, several steps in the protocol were eliminated, including a laborious density cushion step17. This simultaneously enabled an even further downscaling of the method, from the original starting point of using a 10 cm plate per sample16 to using a single well from a 12-well plate per sample (i.e., approximately 15-fold less starting material)17. Fourth, we identified a commercial electroporation apparatus that could replace the custom-made electric discharge capacitor17.
Here our most up-to-date protocol of the LDH sequestration assay, which includes some further simplifications of the method as compared to the previously published17 is presented. Furthermore, a set of typical results obtained in a number of different cell types is shown, and importantly, multiple lines of experimental validations of the method using pharmacological as well as genetic knockdown and knockout approaches are provided. For an overall flow scheme of the whole protocol, see Figure 1.

<table><tbody><tr><td>1.5 mL and 2 mL microcentrifuge tubes&amp;nbsp;</td><td>Eppendorf</td><td>211-2130 and 211-2120</td><td></td></tr><tr><td>12-well plates&amp;nbsp;</td><td>Falcon</td><td>353043</td><td></td></tr><tr><td>Accumax&amp;nbsp; cell detachment solution</td><td>Innovative Cell Technologies</td><td>A7089</td><td>Keep aliquots at -20 &amp;deg;C for years, and in fridge for a few months</td></tr><tr><td>Bafilomycin A1</td><td>Enzo</td><td>BML-CM110-0100</td><td>Dissolve in DMSO</td></tr><tr><td>BJ cells</td><td>ATCC</td><td>CRL-2522</td><td>use at passage &amp;lt;30</td></tr><tr><td>Bovine serum albumin (BSA)</td><td>VWR</td><td>422361V</td><td></td></tr><tr><td>Burker counting chamber</td><td>Fisher Scientific</td><td>139-658585</td><td></td></tr><tr><td>Countess Cell Counting Chamber Slides</td><td>ThermoFisher Scientfic</td><td>C10228</td><td></td></tr><tr><td>Countess II Automated Cell Counter</td><td>ThermoFisher Scientfic</td><td>AMQAX1000</td><td></td></tr><tr><td>Cover glass for the Burker counting chamber</td><td>Fisher Scientific</td><td>139-658586</td><td></td></tr><tr><td>Criterion Tris-HCl Gel, 4&amp;ndash;20%, 26-well, 15 &amp;micro;L, 13.3 cm x 8.7 cm (W x L)&amp;nbsp;</td><td>Bio-Rad</td><td>3450034</td><td></td></tr><tr><td>DTT</td><td>Sigma-Aldrich</td><td>D0632</td><td></td></tr><tr><td>Earle&#039;s balanced salt solution (EBSS)</td><td>Gibco</td><td>24010-043</td><td>conatains 0.1% glucose</td></tr><tr><td>EDTA</td><td>Sigma-Aldrich</td><td>E7889</td><td></td></tr><tr><td>Electroporation cuvette (4 mm)</td><td>Bio-Rad</td><td>1652088</td><td></td></tr><tr><td>Exponential decay wave electroporator</td><td>BTX Harvard Apparatus</td><td>&amp;nbsp;EMC 630</td><td></td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Sigma</td><td>F7524</td><td>10% final concentration in RPMI 1640 medium</td></tr><tr><td>HEK293 cells</td><td>ATCC</td><td>CRL-1573</td><td></td></tr><tr><td>Imidazole</td><td>Sigma-Aldrich</td><td>56750</td><td>Autoclave a 65 mM solution and keep in fridge for months</td></tr><tr><td>Incubator; Autoflow IR Direct Heat CO2 incubator</td><td>NuAire</td><td>NU-5510E</td><td></td></tr><tr><td>Lipofectamine RNAiMAX Transfection Reagent</td><td>ThermoFisher</td><td>13778150</td><td></td></tr><tr><td>LNCaP cells</td><td>ATCC</td><td>CRL-1740</td><td>use at passage &amp;lt;30</td></tr><tr><td>3-Methyl Adenine (3MA)</td><td>Sigma-Aldrich</td><td>M9281</td><td>Stock 100 mM in RPMI in -20 &amp;deg;C.&amp;nbsp; Heat stock to 65 &amp;deg;C for 10 min, and use at 10 mM final concentration</td></tr><tr><td>Refridgerated Microcentrifuge</td><td>Beckman Coulter Life Sciences</td><td>368831</td><td></td></tr><tr><td>Refridgerated Microcentrifuge with soft-mode function</td><td>Eppendorf&amp;nbsp;</td><td>Eppendorf 5417R&amp;nbsp;</td><td></td></tr><tr><td>MRT67307 hydrochloride (ULKi)</td><td>Sigma-Aldrich</td><td>SML0702</td><td>Inhibits ULK kinase activity. Dissolve in DMSO.</td></tr><tr><td>MaxMat Multianalyzer instrument</td><td>Erba Diagnostics</td><td>PL-II</td><td></td></tr><tr><td>MCF7 cells</td><td>ATCC</td><td>HTB-22</td><td></td></tr><tr><td>NADH</td><td>Merck-Millipore</td><td>1.24644.001</td><td></td></tr><tr><td>Nycodenz</td><td>Axis-Shield</td><td>1002424</td><td></td></tr><tr><td>Opti-MEM Reduced Serum Medium</td><td>ThermoFisher</td><td>31985062</td><td></td></tr><tr><td>Phosphate-buffered saline (PBS)</td><td>Gibco</td><td>20012-019</td><td></td></tr><tr><td>Pipette tips 3 (0.5-20 &amp;micro;L)</td><td>VWR</td><td>732-2223</td><td>Thermo Fischer ART Barrier tips</td></tr><tr><td>Pipette tips (1-200 &amp;micro;L)</td><td>VWR</td><td>732-2207&amp;nbsp;</td><td>Thermo Fischer ART Barrier tips</td></tr><tr><td>Pipette tips (100-1,000 &amp;micro;L)</td><td>VWR</td><td>732-2355&amp;nbsp;</td><td>Thermo Fischer ART Barrier tips</td></tr><tr><td>Pipettes</td><td>ThermoFisher</td><td>4701070</td><td>Finnpipette F2 GLP Kit</td></tr><tr><td>Poly-D-lysine</td><td>Sigma-Aldrich</td><td>P6407-10X5MG</td><td>Make a 1 mg/mL stock solution in sterile H&lt;sub&gt;2&lt;/sub&gt;O. This solution is stable at -20 &amp;deg;C for at least 1 year.</td></tr><tr><td>Pyruvate</td><td>Merck-Millipore</td><td>1066190050</td><td></td></tr><tr><td>RPE-1 cells (hTERT RPE-1)</td><td>ATCC</td><td>CRL-4000</td><td></td></tr><tr><td>RPMI 1640</td><td>Gibco</td><td>21875-037</td><td></td></tr><tr><td>SAR-405</td><td>ApexBio&amp;nbsp;</td><td>A8883</td><td>Inhibits phosphoinositide 3-kinase class III (PIK3C3). Dissolve in DMSO.</td></tr><tr><td>Silencer Select Negative Control #1 (siCtrl)</td><td>ThermoFisher/Ambion</td><td>4390843</td><td></td></tr><tr><td>Silencer Select ATG9-targeting siRNA (siATG9A)</td><td>ThermoFisher/Ambion</td><td>s35504</td><td></td></tr><tr><td>Silencer Select FIP200-targeting siRNA (siFIP200)</td><td>ThermoFisher/Ambion</td><td>s18995</td><td></td></tr><tr><td>Silencer Select ULK1-targeting siRNA (siULK1)</td><td>ThermoFisher/Ambion</td><td>s15964</td><td></td></tr><tr><td>Silencer Select ULK2-targeting siRNA (siULK2)</td><td>ThermoFisher/Ambion</td><td>s18705</td><td></td></tr><tr><td>Silencer Select GABARAP-targeting siRNA (siGABARAP)</td><td>ThermoFisher/Ambion</td><td>s22362</td><td></td></tr><tr><td>Silencer Select GABARAPL1-targeting siRNA (siGABARAPL1)</td><td>ThermoFisher/Ambion</td><td>s24333</td><td></td></tr><tr><td>Silencer Select GABARAPL2-targeting siRNA (siGABARAPL2)</td><td>ThermoFisher/Ambion</td><td>s22387</td><td></td></tr><tr><td>Sodium phosphate monobasic dihydrate (NaH&lt;sub&gt;2&lt;/sub&gt;PO4 &amp;bull; 2H&lt;sub&gt;2&lt;/sub&gt;O)&amp;nbsp;</td><td>Merck-Millipore</td><td>1.06580.1000</td><td></td></tr><tr><td>Sodium phosphate dibasic dihydrate (Na&lt;sub&gt;2&lt;/sub&gt;HPO4 &amp;bull; 2H&lt;sub&gt;2&lt;/sub&gt;O )&amp;nbsp;</td><td>Prolabo</td><td>28014.291</td><td></td></tr><tr><td>Sucrose</td><td>VWR</td><td>443816T</td><td>10% final concentration in water; filter through 0.45 &amp;micro;m filter and keep in fridge for months</td></tr><tr><td>Thapsigargin</td><td>Sigma-Aldrich</td><td>T9033</td><td>Inhibits the SERCA ER Ca&lt;sup&gt;2+&lt;/sup&gt; pump. Dissolve in DMSO.</td></tr><tr><td>Triton X-405&amp;nbsp;</td><td>Sigma-Aldrich</td><td>X405</td><td>1% final</td></tr><tr><td>Trypan Blue stain 0.4%</td><td>Molecular Probes</td><td>T10282</td><td></td></tr><tr><td>Trypsin-EDTA (0.25% w/v Trypsin)</td><td>Gibco</td><td>25200-056</td><td></td></tr><tr><td>Tween-20</td><td>Sigma-Aldrich</td><td>P2287</td><td>0.01% final</td></tr></tbody></table>

the lactate dehydrogenase sequestration assay &#8212; a simple and reliable method to determine bulk autophagic sequestration activity in mammalian cells

Bulk autophagy is characterized by the sequestration of large portions of cytoplasm into double/multi-membrane structures termed autophagosomes. Here a simple protocol to monitor this process is described. Moreover, typical results and experimental validation of the method under autophagy-inducing conditions in various types of cultured mammalian cells are provided. During bulk autophagy, autophagosomes sequester cytosol, and thereby also soluble cytosolic proteins, alongside other autophagic cargo. LDH is a stable and highly abundant, soluble cytosolic enzyme that is non-selectively sequestered into autophagosomes. The amount of LDH sequestration therefore reflects the amount of bulk autophagic sequestration. To efficiently and accurately determine LDH sequestration in cells, we employ an electrodisruption-based fractionation protocol that effectively separates sedimentable from cytosolic LDH, followed by measurement of enzymatic activity in sedimentable fractions versus whole-cell samples. Autophagic sequestration is determined by subtracting the proportion of sedimentable LDH in untreated cells from that in treated cells. The advantage of the LDH sequestration assay is that it gives a quantitative measure of the autophagic sequestration of endogenous cargo, as opposed to other methods that either involve ectopic expression of sequestration probes or semi-quantitative protease protection analyses of autophagy markers or receptors.

Using the protocol described here, bulk autophagic sequestration activity in a number of different mammalian cell lines, including LAPC4, DU145, Huh7, PNT2A, HeLa, VCaP, H3122, Hec1A, MCF-7, T47D, U2OS, PC3, G361, mouse embryonic fibroblasts (MEFs), RPE-1, HEK293, BJ, and LNCaP cells was measured. Sequestration was assessed under basal conditions (in complete, nutrient-rich medium), or in cells acutely starved for serum and amino acids (a bona fide autophagy-inducing condition22). The results indicated that LDH sequestration activity under starvation conditions varies extensively across different cell lines, ranging from barely detectable levels in LAPC4, DU145, Huh7 and PNT2 cells (data not shown) to ~1.6%/h in LNCaP cells (Figure 2A). The rate observed in starved primary rat hepatocytes is higher than in the cell lines mentioned above, and typically ranges from 2.5&#8211;4%/h23. Under basal conditions, LDH sequestration was virtually undetectable in half of the cell lines tested, and ranged from ~0.2%/h to ~0.5%/h in the other half (data not shown). In the cell lines that show detectable basal autophagic sequestration activity, acute serum and amino acid starvation typically induces a 3&#8211;4 fold increase in LDH sequestration rate (see for example the LNCaP experiment shown in Figure 2A). In the tested cell lines (mentioned above), the background percentage of sedimented LDH obtained in samples from untreated cells (step 1.3.2) is typically around 2&#8211;3%. From 22 independent experiments performed in various cell lines, the intra-experimental coefficient of variation (CV) between sedimented LDH values (% sedimented LDH) of treatment replicates was 5.8% &#177; 1.7% (average% CV &#177; standard deviation), ranging from 3.0&#8211;9.0%. Together, these numbers give an indication of what to expect when performing the LDH sequestration assay in mammalian cells.
Use of chemical inhibitors as well as genetic knockdown and knockout approaches, extensively verifies that the LDH sequestration assay reliably measures autophagic sequestration activity. Autophagosome formation requires active PI3K class III (PIK3C3) and Unc-51 like autophagy activating kinase (ULK)24, as well as balance in intracellular Ca2+ homeostasis16. As shown in Figure 2A, both basal and starvation-induced LDH sequestration is completely abolished by the pan-PI3K inhibitor 3MA, the selective PIK3C3 inhibitor SAR-40520, or the ER Ca2+ pump inhibitor thapsigargin (TG)25 in LNCaP cells. LDH sequestration under starvation conditions (switch to amino acid-free Earle&#39;s Balanced Salt Solution (EBSS) medium) is also strongly reduced by TG, or by the ULK-inhibitor MRT67307 in HEK293 cells (Figure 2B). Moreover, starvation-induced LDH sequestration is consistently inhibited by 3MA in MEFs (Figure 2C), BJ (Figure 2D), MCF-7 (Figure 2E), and RPE-1 (Figure 2F) cells. Generally, incubation of cells in EBSS medium alone (i.e., in the absence of Baf or other post-sequestration inhibitors) does not lead to any measurable accumulation of sequestered LDH (see for example the LNCaP experiment shown in Figure 2A). This is likely because acute amino acid starvation leads to accelerated autophagic-lysosomal flux, resulting in rapid and continuous degradation of the sequestered LDH.
Next, various ATG gene knockout (KO) MEFs were employed to test whether LDH sequestration requires autophagy-related genes reported to be essential for autophagosome formation. Indeed, starvation-induced LDH sequestration is abolished in ATG5 KO MEFs26 (Figure 3A), confirming our previous findings9. Moreover, as shown in Figure 3B and 3C, starvation-induced LDH sequestration is blunted also in ATG7 KO MEFs27 and ATG9A KO MEFs28.
Finally, the LDH sequestration assay was tested in relation to whether RNAi-mediated silencing of key ATG gene transcripts would inhibit starvation-induced sequestration activity. Indeed, transfection with an ATG9A-targeting siRNA, or combined targeting of ULK1 and ULK2, strongly reduced LDH sequestration under starvation conditions in LNCaP cells (Figure 3D). Moreover, we confirmed our previous findings3,9 that targeting of focal adhesion kinase family interacting protein of 200 kDa (FIP200) or combined targeting of the &#947;-aminobutyric acid type A (GABAA) receptor-associated protein (GABARAP) family members inhibits starvation-induced LDH sequestration (Figure 3D).
<img alt="Figure 1" class="xfigimg" src="/files/ftp_upload/57971/57971fig1v3.jpg" /> 
Figure 1: Overall flow scheme of the LDH sequestration protocol. The protocol is based on a 12-well tissue culture plate format, using the indicated volumes per sample (from one well). The assay protocol can conveniently be divided into two separate working days, as indicated. However, it is also possible to perform the whole procedure in one day. Abbreviations: ABB, after blast buffer (see step 3.3 in the protocol for ingredients); RSB, resuspension buffer (see step 3.5 in the protocol for ingredients).&#160;<a href="https://www-jove-com.bdigitaluss.remotexs.co/files/ftp_upload/57971/57971fig1v3large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 2" class="xfigimg" src="/files/ftp_upload/57971/57971fig2v5.jpg" /> 
Figure 2: Validation of the LDH sequestration assay using autophagy-inhibiting compounds. (A) LNCaP cells were either left untreated (for the purpose of background subtraction: see step 1.3.2) in complete growth medium (CM; RPMI 1640 + 10% fetal bovine serum (FBS)), or they were treated with DMSO vehicle (0.1%) or 100 nM Baf in CM or in serum- and amino acid free medium (EBSS). Additionally, some of the cells were treated with 3MA (10 mM), SAR-405 (10 &#181;M), or Thapsigargin&#160;(300 nM), as indicated. After 3 h of treatment, the cells were harvested, and LDH sequestration rates were determined as detailed in the current protocol. (B) HEK293 cells were treated with DMSO vehicle (0.1%) in CM, or with 100 nM Baf in EBSS, as indicated. Additionally, some of the cells received 10 &#181;M MRT67307 (an ULK inhibitor) or 300 nM Thapsigargin. LDH sequestration rates were determined after 3 h of treatment. (C-F) MEF (C), BJ (D), MCF-7 (E), or RPE-1 (F) cells were treated with DMSO vehicle (0.1%) in CM, or with Baf (10 nM in C, 100 nM in D-F) in EBSS with or without 10 mM 3MA, as indicated. LDH sequestration rates were determined after 3 h of treatment. A, B, D, E, and F show mean values from three biological replicates (triplicate wells) from one experiment (n = 1), with error bars representing standard deviation. C shows the mean values from three independent experiments (n = 3), with error bars representing standard error of the mean. *p &#60;0.05, ***p &#60;0.001, repeated samples one-way ANOVA.&#160;
<img alt="Figure 3" class="xfigimg" src="/files/ftp_upload/57971/57971fig3v3.jpg" /> 
Figure 3: Validation of the LDH sequestration assay by knockout (A-C) or knockdown (D) approaches. (A-C) ATG5 wild type (WT) or knockout (KO) MEFs (A), ATG7 WT or KO MEFs (B), or ATG9A WT or KO MEFs (C) were treated with DMSO vehicle (0.01%) in CM, or with 10 nM Baf in EBSS, as indicated. LDH sequestration rates were determined after 3 h of treatment. Mean values from four (A; n = 4) or three (B and C; n = 3) independent experiments, with error bars representing standard error of the mean. *p &#60;0.05, repeated samples two-way ANOVA. N.S., not significant. (D) LNCaP cells were reverse transfected with 5 nM of a nontargeting control siRNA (siCtrl), or with 5 nM each of ATG9A-, FIP200-, ULK1-, ULK2-, GABARAP-, GABARAPL1-, or GABARAPL2-targeting siRNA oligoes, as indicated. After 48 h, the cells were either treated with DMSO vehicle (0.1%) in CM, or with 100 nM Baf in EBSS, as indicated. LDH sequestration rates were determined after 3 h of treatment. Shown are mean values from three biological replicates (triplicate wells) from one experiment (n = 1), with error bars representing standard deviation.&#160;

Watch this Scientific Journal Video about The Lactate Dehydrogenase Sequestration Assay â€” A Simple and Reliable Method to Determine Bulk Autophagic Sequestration Activity in Mammalian Cells at 

The Lactate Dehydrogenase Sequestration Assay &#8212; A Simple and Reliable Method to Determine Bulk Autophagic Sequestration Activity in Mammalian Cells

Here a simple and well-validated protocol for measuring bulk autophagic sequestration activity in mammalian cells is described. The method is based on quantifying the proportion of lactate dehydrogenase (LDH) in sedimentable cell fractions compared to total cellular LDH levels.

Bulk autophagy is characterized by the sequestration of large portions of cytoplasm into double/multi-membrane structures termed autophagosomes. Here a ...

the-lactate-dehydrogenase-sequestration-assay-simple-reliable-method

Universidad San Sebastian

Research

JoVE Journal

Biology

18.0K Views.  University of Oslo. Here a simple and well-validated protocol for measuring bulk autophagic sequestration activity in mammalian cells is described. The method is based on quantifying the proportion of lactate dehydrogenase (LDH) in sedimentable cell fractions compared to total cellular LDH levels.

Video: The Lactate Dehydrogenase Sequestration Assay — A Simple and Reliable Method to Determine Bulk Autophagic Sequestration Activity in Mammalian Cells

Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue

Mapping enzymatic activity in space and time is critical for understanding the molecular basis of cell behavior in normal tissue and disease. In situ metabolic activity assays can provide information about the spatial distribution of metabolic activity within a tissue. We provide here a detailed protocol for monitoring the activity of the enzyme lactate dehydrogenase directly in tissue samples. Lactate dehydrogenase is an important determinant of whether consumed glucose will be converted to energy via aerobic or anaerobic glycolysis. A solution containing lactate and NAD is provided to a frozen tissue section. Cells with high lactate dehydrogenase activity will convert the provided lactate to pyruvate, while simultaneously converting provided nicotinamide adenine dinucleotide (NAD) to NADH and a proton, which can be detected based on the reduction of nitrotetrazolium blue to formazan, which is visualized as a blue precipitate. We describe a detailed protocol for monitoring lactate dehydrogenase activity in mouse skin. Applying this protocol, we found that lactate dehydrogenase activity is high in the quiescent hair follicle stem cells within the skin. Applying the protocol to cultured mouse embryonic stem cells revealed higher staining in cultured embryonic stem cells than mouse embryonic fibroblasts. Analysis of freshly isolated mouse aorta revealed staining in smooth muscle cells perpendicular to the aorta. The methodology provided can be used to spatially map the activity of enzymes that generate a proton in frozen or fresh tissue.

We describe a protocol for mapping the spatial distribution of enzymatic activity for enzymes that generate nicotinatmide adenine dinucleotide phosphate (NAD(P)H) + H+ directly in tissue samples.

Mapping enzymatic activity in space and time is critical for understanding the molecular basis of cell behavior in normal tissue and disease. In situ ...

Biochemistry

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Macroautophagy, commonly referred to as autophagy, is a highly conserved cellular process responsible for the degradation of cellular components. This process is particularly prominent under conditions such as fasting, cellular stress, organelle damage, cellular damage, or aging of cellular components. During autophagy, a segment of the cytoplasm is enclosed within double-membrane vesicles known as autophagosomes, which then fuse with lysosomes. Following this fusion, the contents of autophagosomes undergo non-selective bulk degradation facilitated by lysosomes. However, autophagy also exhibits selective functionality, targeting specific organelles, including mitochondria, peroxisomes, lysosomes, nuclei, and lipid droplets (LDs). Lipid droplets are enclosed by a phospholipid monolayer that isolates neutral lipids from the cytoplasm, protecting cells from the harmful effects of excess sterols and free fatty acids (FFAs). Autophagy is implicated in various conditions, including neurodegenerative diseases, metabolic disorders, and cancer. Specifically, lipophagy -- the autophagy-dependent degradation of lipid droplets -- plays a crucial role in regulating intracellular FFA levels across different metabolic states. This regulation supports essential processes such as membrane synthesis, signaling molecule formation, and energy balance. Consequently, impaired lipophagy increases cellular vulnerability to death stimuli and contributes to the development of diseases such as cancer. Despite its significance, the precise mechanisms governing lipid droplet metabolism regulated by lipophagy in cancer cells remain poorly understood. This article aims to describe confocal imaging acquisition and quantitative imaging analysis protocols that enable the investigation of lipophagy associated with metabolic changes in cancer cells. The results obtained through these protocols may shed light on the intricate interplay between autophagy, lipid metabolism, and cancer progression. By elucidating these mechanisms, novel therapeutic targets may emerge for combating cancer and other metabolic-related diseases.

Lipophagy is a selective form of autophagy that involves the degradation of lipid droplets. Dysfunctions in this process are associated with cancer development. However, the precise mechanisms are not yet fully understood. This protocol describes quantitative imaging approaches to better understand the interplay between autophagy, lipid metabolism, and cancer progression.

Macroautophagy, commonly referred to as autophagy, is a highly conserved cellular process responsible for the degradation of cellular components. This ...

Cancer Research

Assessing LC3-II-Positive EV Release in Autophagy with Impaired Lysosome Fusion

Evaluation of LC3-II Release via Extracellular Vesicles in Relation to the Accumulation of Intracellular LC3-positive Vesicles

(Macro)autophagy represents a fundamental cellular degradation pathway. In this process, double-membraned vesicles known as autophagosomes engulf cytoplasmic contents, subsequently fusing with lysosomes for degradation. Beyond the canonical role, autophagy-related genes also modulate a secretory pathway involving the release of inflammatory molecules, tissue repair factors, and extracellular vesicles (EVs). Notably, the process of disseminating pathological proteins between cells, particularly in neurodegenerative diseases affecting the brain and spinal cord, underscores the significance of understanding this phenomenon. Recent research suggests that the transactive response DNA-binding protein 43 kDa (TDP-43), a key player in amyotrophic lateral sclerosis and frontotemporal lobar degeneration, is released in an autophagy-dependent manner via EVs enriched with the autophagosome marker microtubule-associated proteins 1A/1B light chain 3B-II (LC3-II), especially when autophagosome-lysosome fusion is inhibited.
To elucidate the mechanism underlying the formation and release of LC3-II-positive EVs, it is imperative to establish an accessible and reproducible method for evaluating both intracellular and extracellular LC3-II-positive vesicles. This study presents a detailed protocol for assessing LC3-II levels via immunoblotting in cellular and EV fractions obtained through differential centrifugation. Bafilomycin A1 (Baf), an inhibitor of autophagosome-lysosome fusion, serves as a positive control to enhance the levels of intracellular and extracellular LC3-II-positive vesicles. Tumor susceptibility gene 101 (TSG101) is used as a marker for multivesicular bodies. Applying this protocol, it is demonstrated that siRNA-mediated knockdown of syntaxin-6 (STX6), a genetic risk factor for sporadic Creutzfeldt-Jakob disease, augments LC3-II levels in the EV fraction of cells treated with Baf while showing no significant effect on TSG101 levels. These findings suggest that STX6 may negatively regulate the extracellular release of LC3-II via EVs, particularly under conditions where autophagosome-lysosome fusion is impaired. Combined with established methods for evaluating autophagy, this protocol provides valuable insights into the role of specific molecules in the formation and release of LC3-II-positive EVs.

Here, we present the methodology for concisely assessing autophagosome marker LC3-II levels in extracellular vesicles (EVs) by immunoblotting. Analysis for LC3-II levels in EVs, autolysosome formation, and omegasome formation suggests the new role of STX6 in the release of LC3-II-positive EVs when autophagosome-lysosome fusion is inhibited.

(Macro)autophagy represents a fundamental cellular degradation pathway. In this process, double-membraned vesicles known as autophagosomes engulf ...

In Vitro and In Vivo Detection of Mitophagy in Human Cells, C. Elegans, and Mice

Mitochondria are the powerhouses of cells and produce cellular energy in the form of ATP. Mitochondrial dysfunction contributes to biological aging and a wide variety of disorders including metabolic diseases, premature aging syndromes, and neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Maintenance of mitochondrial health depends on mitochondrial biogenesis and the efficient clearance of dysfunctional mitochondria through mitophagy. Experimental methods to accurately detect autophagy/mitophagy, especially in animal models, have been challenging to develop. Recent progress towards the understanding of the molecular mechanisms of mitophagy has enabled the development of novel mitophagy detection techniques. Here, we introduce several versatile techniques to monitor mitophagy in human cells, Caenorhabditis elegans (e.g., Rosella and DCT-1/ LGG-1 strains), and mice (mt-Keima). A combination of these mitophagy detection techniques, including cross-species evaluation, will improve the accuracy of mitophagy measurements and lead to a better understanding of the role of mitophagy in health and disease.

In Vitro and In Vivo Detection of Mitophagy in Human Cells, C. Elegans, and Mice

Mitophagy, the process of clearing damaged mitochondria, is necessary for mitochondrial homeostasis and health maintenance. This article presents some of the latest mitophagy detection methods in human cells, Caenorhabditis elegans, and mice.

Mitochondria are the powerhouses of cells and produce cellular energy in the form of ATP. Mitochondrial dysfunction contributes to biological aging and a ...

Medicine

Activating Autophagy by Aerobic Exercise in Mice

Autophagy is a lysosomal degradation pathway essential for cell homeostasis, function and differentiation. Under stress conditions, autophagy is induced and targets various cargos, such as bulk cytosol, damaged organelles and misfolded proteins, for degradation in lysosomes. Resulting nutrient molecules are recycled back to the cytosol for new protein synthesis and ATP production. Upregulation of autophagy has beneficial effects against the pathogenesis of many diseases, and pharmacological and physiological strategies to activate autophagy have been reported. Aerobic exercise is recently identified as an efficient autophagy inducer in multiple organs in mice, including muscle, liver, heart and brain. Here we show procedures to induce autophagy in vivo by either forced treadmill exercise or voluntary wheel running. We also demonstrate microscopic and biochemical methods to quantitatively analyze autophagy levels in mouse tissues, using the marker proteins LC3 and p62 that are transported to and degraded in lysosomes along with autophagosomes.

Autophagy activation is beneficial in the prevention of a number of diseases. One of the physiological approaches to induce autophagy in vivo is physical exercise. Here we show how to activate autophagy by aerobic exercise and measure autophagy levels in mice.

Autophagy is a lysosomal degradation pathway essential for cell homeostasis, function and differentiation. Under stress conditions, autophagy is induced ...

Assessing Autophagic Flux by Measuring LC3, p62, and LAMP1 Co-localization Using Multispectral Imaging Flow Cytometry

Autophagy is a catabolic pathway in which normal or dysfunctional cellular components that accumulate during growth and differentiation are degraded via the lysosome and are recycled. During autophagy, cytoplasmic LC3 protein is lipidated and recruited to the autophagosomal membranes. The autophagosome then fuses with the lysosome to form the autolysosome, where the breakdown of the autophagosome vesicle and its contents occurs. The ubiquitin-associated protein p62, which binds to LC3, is also used to monitor autophagic flux. Cells undergoing autophagy should demonstrate the co-localization of p62, LC3, and lysosomal markers. Immunofluorescence microscopy has been used to visually identify LC3 puncta, p62, and/or lysosomes on a per-cell basis. However, an objective and statistically rigorous assessment can be difficult to obtain. To overcome these problems, multispectral imaging flow cytometry was used along with an analytical feature that compares the bright detail images from three autophagy markers (LC3, p62 and lysosomal LAMP1) and quantifies their co-localization, in combination with LC3 spot counting to measure autophagy in an objective, quantitative, and statistically robust manner.

Here, multispectral imaging flow cytometry with an analytical feature that compares bright detail images of 3 autophagy markers and quantifies their co-localization, along with LC3 spot counting, was used to measure autophagy in an objective, quantitative, and statistically robust manner.

Autophagy is a catabolic pathway in which normal or dysfunctional cellular components that accumulate during growth and differentiation are degraded via ...

Flux-Based Assay for the Identification of Autophagy Modulators for Osteoarthritis

Autophagy is a central mechanism to regulate homeostasis. Alterations of autophagy contribute to aging-related diseases. Phenotypic methods to identify regulators of autophagy could be used for the identification of novel therapeutics. This article describes a cell-based imaging screening workflow developed to monitor autophagic flux using LC3 as a reporter of autophagic flux (mCherry-EGFP-LC3B) in human chondrocytes. Data acquisition is performed using an automated High Content Imaging Screening System microscope. An algorithm-based automated image analysis protocol was developed and validated to identify molecules activating autophagic flux. Critical steps, explanatory notes, and improvements over current autophagy monitoring protocols are reported. Physiologically relevant phenotypic screening approaches to target hallmarks of aging can facilitate more effective drug discovery strategies for age-related musculoskeletal diseases.

This paper details monitoring autophagy flux to identify new molecules by cell-based imaging screening.

Autophagy is a central mechanism to regulate homeostasis. Alterations of autophagy contribute to aging-related diseases. Phenotypic methods to identify ...

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Autophagy is a specialized catabolic process that selectively degrades cytoplasmic components, including proteins and damaged organelles. Autophagy allows cells to physiologically respond to stress stimuli and, thus, maintain cellular homeostasis. Cancer cells might modulate their autophagy levels to adapt to adverse conditions such as hypoxia, nutrient deficiency, or damage caused by chemotherapy. Ductal pancreatic adenocarcinoma is one of the deadliest types of cancer. Pancreatic cancer cells have high autophagy activity due to the transcriptional upregulation and post-translational activation of autophagy proteins.
Here, the PANC-1 cell line was used as a model of pancreatic human cancer cells, and the AR42J pancreatic acinar cell line was used as a physiological model of highly differentiated mammalian cells. This study used the immunofluorescence of microtubule-associated protein light chain 3 (LC3) as an indicator of the status of autophagy activation. LC3 is an autophagy protein that, in basal conditions, shows a diffuse pattern of distribution in the cytoplasm (known as LC3-I in this condition). Autophagy induction triggers the conjugation of LC3 to phosphatidylethanolamine on the surface of newly formed autophagosomes to form LC3-II, a membrane-bound protein that aids in the formation and expansion of autophagosomes. To quantify the number of labeled autophagic structures, the open-source software FIJI was utilized with the aid of the &#34;3D Objects Counter&#34; tool.
The measure of the autophagic levels both in physiological conditions and in cancer cells allows us to study the modulation of autophagy under diverse conditions such as hypoxia, chemotherapy treatment, or the knockdown of certain proteins.

The goal of this protocol is to determine autophagic levels in pancreatic cancer and pancreatic acinar cells through LC3 immunofluorescence and LC3 dot quantification.

Autophagy is a specialized catabolic process that selectively degrades cytoplasmic components, including proteins and damaged organelles. Autophagy allows ...

High-Throughput Screening Analysis for 4B Cysteine Peptidase Autophagy Inhibitor

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Growing evidence has shown that high autophagic flux is related to tumor progression and cancer therapy resistance. Assaying individual autophagy proteins is a prerequisite for therapeutic strategies targeting this pathway. Inhibition of the autophagy protease ATG4B has been shown to increase overall survival, suggesting that ATG4B could be a potential drug target for cancer therapy. Our laboratory has developed a selective luciferase-based assay for monitoring ATG4B activity in cells. For this assay, the substrate of ATG4B, LC3B, is tagged at the C-terminus with a secretable luciferase from the marine copepod Gaussia princeps (GLUC). This reporter is linked to the actin cytoskeleton, thus keeping it in the cytoplasm of cells when uncleaved. ATG4B-mediated cleavage results in the release of GLUC by non-conventional secretion, which then can be monitored by harvesting supernatants from cell culture as a correlate of cellular ATG4B activity. This paper presents the adaptation of this luciferase-based assay to automated high-throughput screening. We describe the workflow and optimization for exemplary high-throughput analysis of cellular ATG4B activity.

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells 

Here, we describe a detailed protocol for the use of a luciferase-based reporter assay in a semi-automated, high-throughput screening format.

Growing evidence has shown that high autophagic flux is related to tumor progression and cancer therapy resistance. Assaying individual autophagy proteins ...

Quantifying Bulk Autophagic Sequestration Activity in Mammalian Cells

Source: Luhr, M. et al., <a href="https://app-jove-com.bdigitaluss.remotexs.co/v/57971">The Lactate Dehydrogenase Sequestration Assay &#8212; A Simple and Reliable Method to Determine Bulk Autophagic Sequestration Activity in Mammalian Cells.</a> J. Vis. Exp. (2018)
The video demonstrates an assay for assessing bulk autophagic sequestration activity in mammalian cells. It utilizes electroporation to release cytosolic proteins, including lactate dehydrogenase (LDH). The sequestered LDH and total cellular LDH fractions are determined to assess LDH sequestration, providing insights into the overall bulk sequestration activity.

1. Cell Seeding and Treatment

	Culture adherent cells in 75 cm2&#160;tissue culture flasks in a humidified incubator with 5% CO2&#160;at 37 &#176;C, ...

The Lactate Dehydrogenase Sequestration Assay — A Simple and Reliable Method to Determine Bulk Autophagic Sequestration Activity in Mammalian Cells

Summary

Explore More Videos

Chapters in this video

Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Evaluation of LC3-II Release via Extracellular Vesicles in Relation to the Accumulation of Intracellular LC3-positive Vesicles

In Vitro and In Vivo Detection of Mitophagy in Human Cells, C. Elegans, and Mice

Activating Autophagy by Aerobic Exercise in Mice

Assessing Autophagic Flux by Measuring LC3, p62, and LAMP1 Co-localization Using Multispectral Imaging Flow Cytometry

Flux-Based Assay for the Identification of Autophagy Modulators for Osteoarthritis

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Quantifying Bulk Autophagic Sequestration Activity in Mammalian Cells